EI
REGN icon

EFG International’s Regeneron Pharmaceuticals REGN Stock Holding History

EFG International’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Sell
1,840
-100
-5% -$68.1K 0.02% 405
2026
Q1 		$1.5M Buy
1,940
+55
+3% +$42.1K 0.03% 364
2025
Q4 		$1.45M Buy
+1,885
New +$1.28M 0.03% 342

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

EFG International's REGN Position: Q2 2026 in Review

EFG International reduced its Regeneron Pharmaceuticals (REGN) stake by 5.2% in Q2 2026, selling an estimated $68.1K and leaving 1,840 shares worth $1.15M. The position accounts for 0.02% of the portfolio, ranked #405.

EFG International first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.5M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • EFG International held 1,840 shares of Regeneron Pharmaceuticals worth $1.15M as of Q2 2026.
  • EFG International sold 100 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $68.1K.
  • Regeneron Pharmaceuticals made up 0.02% of EFG International's portfolio in Q2 2026, its #405 holding.
  • EFG International first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • EFG International's Regeneron Pharmaceuticals position peaked at $1.5M in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on EFG International's 13F filing for Q2 2026, filed 14 Aug 2026.